EUVIMEDEUVIMED entdecken
Open Access · CC0

An adjuvant formulation containing Toll-like Receptor 7 agonist stimulates protection against morbidity and mortality due to Anaplasma marginale in a highly endemic region of west Africa

James E Futse iD, Songliedong Zumor-Baligi, Charles N K Ashiagbor, Susan M Noh iD, Christopher B Fox, Guy H Palmer

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von James E Futse und 5 weiteren Autor:innen. Beteiligte Einrichtung: Animal Disease Biotechnology Laboratory, Department of Animal Science, School of Agriculture, College of Basic and Applied Sciences, University of Gh…. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Anaplasma marginale, Cattle Diseases, Anaplasmosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Bill and Melinda Gates Foundation, Paul G. Allen School for Global Health at Washington State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efficient cattle production and provision of animal-sourced foods in much of Africa is constrained by vector-borne bacterial and protozoal diseases. Effective vaccines are not currently available for most of these infections resulting in a continuous disease burden that limits genetic improvement. We tested whether stimulation of innate immunity using the Toll-like Receptor (TLR) 7 agonist imiquimod, formulated with saponin and water-in-oil emulsion, would protect against morbidity and mortality due to Anaplasma marginale , a tick-borne pathogen of cattle highly endemic in west Africa. In Trial 1, haplotype matched Friesian x Sanga (F1) A . marginale negative calves were allocated to either the experimental group (n = 10) and injected with the synthetic TLR 7 agonist/saponin formulation or to an untreated control group (n = 10). TLR7 agonist/saponin injected calves responded with significantly elevated rectal temperature, enlarged regional lymph nodes, and elevated levels of IL-6 post-injection as compared to control group calves. All calves were then allowed to graze in pasture for natural exposure to tick transmission. All calves in both groups acquired A . marginale , consistent with the high transmission rate in the endemic region. The need for antibiotic treatment, using pre-existing criteria, was significantly lower in the experimental group (odds ratio for not requiring treatment was 9.3, p = 0.03) as compared to the control group. Despite treatment, 6/10 calves in the control group died, reflecting treatment failures that are typical of anaplasmosis in the acute phase, while mortality in the experimental group was 1/10 (odds ratio for survival was 13.5, p = 0.03). The trial was then repeated using 45 Friesian x Sanga calves per group. In Trial 2, the odds ratios for preventing the need for treatment and for mortality in the TLR7 agonist/saponin experimental group versus the control group were 5.6 (p = 0.0002) and 7.0 (p = 0.004), respectively, reproducing the findings of the initial trial. Together these findings demonstrate that innate immune stimulation using a TLR7 agonist formulated with saponin and water-in-oil emulsion provides significant protection against disease caused by tick borne A . marginale in highly susceptible cross-bred cattle, critically important for their potential to increase productivity for smallholder farmers in Africa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Anaplasma marginaleCattle DiseasesAnaplasmosisAdjuvants, ImmunologicAnimalsCattleAfrica, WesternImiquimodSaponinsEndemic Diseases

Substanzen

Toll-Like Receptor 7Adjuvants, ImmunologicImiquimodSaponins

Autor:innen und Institutionen

  • Animal Disease Biotechnology Laboratory, Department of Animal Science, School of Agriculture, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana.
  • Animal Diseases Research Unit, USDA-ARS, Pullman, Washington, United States of America.
  • Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington, United States of America.
  • Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, United States of America.
  • Access to Advanced Health Institute, Seattle, Washington, United States of America.
  • Department of Global Health, University of Washington, Seattle, Washington, United States of America.

ORCID-Profile: James E Futse, Susan M Noh

Förderung

  • Bill and Melinda Gates Foundation
  • Paul G. Allen School for Global Health at Washington State University

Zitieren

APA

Futse, J. E., Zumor-Baligi, S., Ashiagbor, C. N. K., Noh, S. M., Fox, C. B., & Palmer, G. H. (2024). An adjuvant formulation containing Toll-like Receptor 7 agonist stimulates protection against morbidity and mortality due to Anaplasma marginale in a highly endemic region of west Africa. PLOS ONE. https://doi.org/10.1371/journal.pone.0306092

Vancouver

Futse JE, Zumor-Baligi S, Ashiagbor CNK, Noh SM, Fox CB, Palmer GH. An adjuvant formulation containing Toll-like Receptor 7 agonist stimulates protection against morbidity and mortality due to Anaplasma marginale in a highly endemic region of west Africa. PLOS ONE. 2024. doi:10.1371/journal.pone.0306092

BibTeX
@article{Futse2024,
  author = {Futse, James E and Zumor-Baligi, Songliedong and Ashiagbor, Charles N K and Noh, Susan M and Fox, Christopher B and Palmer, Guy H},
  title = {An adjuvant formulation containing Toll-like Receptor 7 agonist stimulates protection against morbidity and mortality due to Anaplasma marginale in a highly endemic region of west Africa},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306092}
}
Kostenlos starten →